MENRIUM 5-4

LOE Approaching

Roche

NDAORALTABLET

Approved

Jul 1966

Lifecycle

LOE Approaching

Competitive Pressure

30/100

Data completeness

1/8 — Limited

Drug data last refreshed 6d ago · AI intelligence enriched 3w ago

AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data

MENRIUM 5-4 is an oral tablet approved by Roche in 1966 for an unknown indication. The mechanism of action and pharmacologic class are not specified in available data.

LOE Approaching

This product is in late-stage lifecycle with LOE approaching, suggesting a small, consolidating commercial team focused on managing decline rather than growth.

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Career Relevance

Zero linked job openings indicate minimal hiring activity around this product. Working on MENRIUM 5-4 would involve managing a mature, declining asset with limited growth opportunities.

Company

Worked on MENRIUM 5-4 at Roche? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.